Fig. 5
Association of baseline sGFAP and sNfL with time to a future attack in patients with AQP4-IgG+ NMOSD. a Patients with AQP4-IgG+ NMOSD (n = 33) were grouped into those with “high” and “low” baseline sGFAP values, using a sGFAP value of 90 pg/ml, derived from 75th sGFAP percentile in healthy controls (90.7 pg/ml), as cut-off. The survival curves show the adjusted cumulative attack free survival probability in patients with baseline sGFAP ≤ or > 90 pg/ml. b Patients with AQP4-IgG+ NMOSD (n = 33) were grouped into those with “high” and “low” baseline sNfL values using the 75th age-adjusted percentile as cut-off. The survival curves show the adjusted cumulative attack free survival probability in patients with baseline sNfL ≤ or > 75th age-adjusted percentile. Hazard ratios (HR) with 95% confidence intervals (CI) calculated by Cox regression analyses adjusted for age and time since last attack prior to study inclusion and p values are indicated. The number of patients at risk for an attack in each group is indicated below the graphs. CI confidence interval, NMOSD neuromyelitis optica spectrum disorder, HR hazard ratio, sGFAP serum glial fibrillary acidic protein, sNfL serum neurofilament light chain protein